JOINT FILING AGREEMENTJoint Filing Agreement • February 21st, 2024 • Orbimed Advisors LLC • Pharmaceutical preparations
Contract Type FiledFebruary 21st, 2024 Company IndustryThe undersigned hereby agree that Amendment No. 6 to the Statement on Schedule 13D, dated February 16, 2024, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • November 17th, 2023 • Orbimed Advisors LLC • Pharmaceutical preparations
Contract Type FiledNovember 17th, 2023 Company IndustryThe undersigned hereby agree that the Amendment No. 5 to the Statement on Schedule 13D, dated November 17, 2023, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • November 14th, 2023 • Orbimed Advisors LLC • Pharmaceutical preparations
Contract Type FiledNovember 14th, 2023 Company IndustryThe undersigned hereby agree that the Amendment No. 4 to the Statement on Schedule 13D, dated November 13, 2023, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • May 8th, 2023 • Orbimed Advisors LLC • Pharmaceutical preparations
Contract Type FiledMay 8th, 2023 Company IndustryThe undersigned hereby agree that the Amendment No. 3 to the Statement on Schedule 13D, dated May 4, 2023, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • May 3rd, 2023 • Orbimed Advisors LLC • Pharmaceutical preparations
Contract Type FiledMay 3rd, 2023 Company IndustryThe undersigned hereby agree that the Amendment No. 2 to the Statement on Schedule 13D, dated April 28, 2023, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • February 23rd, 2023 • Orbimed Advisors LLC • Pharmaceutical preparations
Contract Type FiledFebruary 23rd, 2023 Company IndustryThe undersigned hereby agree that the Statement on Schedule 13D, dated February 17, 2023, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.